

Cardiovascular and Renal Drugs Advisory Committee
Meeting
December 9, 2003
Agenda

Hilton, The Ballrooms, Gaithersburg, MD

8:00 - 8:10 a.m. Call to Order and Introductions	Jeffery Borer, M.D. Chair, Cardiovascular and Renal Drugs Advisory Committee
Conflict of Interest Statement	Dornette Spell-LeSane, M.H.A., NP-C Executive Secretary, FDA
8:30 - 8:45 a.m. Welcome and Introductory Comments	Douglas Throckmorton, M.D. Division of Cardiovascular and Renal Drugs FDA

**The committee will discuss new drug application NDA 21-526 CV Therapeutics
Proposed tradename Ranexa (ranolazine) 375 mg and 500 mg tablets
for treatment of chronic stable angina**

8:45 a.m. **Sponsor Presentation**

CV Therapeutics

10:15 – 10:30	Break
10:30 – 10:45	Questions from the Committee
10:45 – 12:00	Committee Discussions
12:00 – 1:00	Lunch
1:00 – 1:30	Open Public Hearing
1:30 – 2:30	Committee Discussions
2:30 – 3:30	Committee Questions
3:30 – 3:45	Break
3:45 – 4:30	Questions/ Summary
4:30 p.m.	Adjournment